Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations

Pharmacokinetics‐matched digital electrocardiogram data (n = 503 measurements from 180 patients) collected in a first‐in‐human, multi‐part, dose‐escalation (from 80 to 800 mg) and dose expansion (at 480 mg) phase 1 study in patients with advanced solid malignancies, were used to assess potential ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Voronova, Veronika, Cullberg, Marie, Delff, Philip, Parkinson, Joanna, Dota, Corina, Schiavon, Gaia, Maroj, Brijesh, Rekić, Dinko, Cheung, S. Y. Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292875/
https://www.ncbi.nlm.nih.gov/pubmed/34309049
http://dx.doi.org/10.1111/bcp.15006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292875/
https://www.ncbi.nlm.nih.gov/pubmed/34309049
http://dx.doi.org/10.1111/bcp.15006

Ejemplares similares